-
-
-
-
-
-
-
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5
-
-
-
-
-
-
-
Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results
-
-
-
-
-
-
-
Calidi Biotherapeutics (CLDI) Presents CLD-101 Phase 1 Trial Update, Preclinical Data Highlighting RTNova and CLD-201
-
-
-
-
-
-
-
Form S-1/A Calidi Biotherapeutics,
-
-
-
-
-
-
-
Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer
-
-
-
-
-
-
-
Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit
-
-
-
-
-
-
-
Calidi Biotherapeutics (CLDI) (CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity
-
67,019 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

